GeneDx Holdings (WGS) Liabilities and Shareholders Equity (2020 - 2026)

GeneDx Holdings (WGS) has reported Liabilities and Shareholders Equity for 7 consecutive years, with $506.3 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Liabilities and Shareholders Equity rose 13.41% year-over-year to $506.3 million; the TTM figure through Mar 2026 stood at $2.0 billion (up 19.48% YoY), while the FY2025 annual figure was $523.7 million, up 24.88% from the prior year.
• Liabilities and Shareholders Equity slipped to $506.3 million in Q1 2026 per WGS's latest filing, from $523.7 million in the prior quarter.
• Across five years, Liabilities and Shareholders Equity topped out at $933.3 million in Q2 2022 and bottomed at $389.1 million in Q2 2024.
• Historically, Liabilities and Shareholders Equity has averaged $510.3 million across 5 years, with a median of $476.4 million in 2023.
• Annual changes were most pronounced in 2022 — Liabilities and Shareholders Equity soared 431.68% — and 2023, when it plunged 49.66%.
• GeneDx Holdings' Liabilities and Shareholders Equity stood at $490.9 million in 2022, then decreased by 14.7% to $418.8 million in 2023, then increased by 0.15% to $419.4 million in 2024, then rose by 24.88% to $523.7 million in 2025, then fell by 3.32% to $506.3 million in 2026.
• Business Quant data shows WGS's Liabilities and Shareholders Equity at $506.3 million in Q1 2026, $523.7 million in Q4 2025, and $493.9 million in Q3 2025.